Preparing early for acquisition: how biotech companies can build value long before a deal
The strongest acquisition outcomes are shaped years before conversations with acquirers begin. Every development decision provides opportunity, yet many biotechs focus so intently on the next clinical milestone that they often miss the chance to build value along the way.
This playbook from Parexel and Health Advances shows you how to see your asset the way an acquirer will. Discover how to build deal-ready evidence, de-risk program vulnerabilities and create a value story that differentiates your innovation.
Related Insights
CTB Blog
EMA’s new pre-submission interactions model pilot: A fundamental shift toward submission readiness and predictable reviews
Sep 30, 2026
CTB Blog
Engage early, design once: turning early-phase trials into a program strategy
Sep 10, 2026
CTB Blog
Five Practical Strategies for Accelerating Early Phase Studies
Aug 19, 2026
Article
Reading current FDA and NMPA trends: What oncology tells us about the changing regulatory landscape
Jul 21, 2026
CTB Blog
Modernizing data operations to enable today's Phase 1 trials
Jul 1, 2026
Blog
A Deep Dive into the Genetic Therapies Bootcamp at the ACMG 2026 Annual Meeting
Jun 23, 2026
Video
Bench-to-bedside: Transforming scientific breakthroughs into clinical success
Apr 3, 2026
CTB Blog
Even when capital flows freely, biotechs benefit from efficiency
Mar 24, 2026
CTB Blog
5 ways to secure biotech funding in 2026
Mar 19, 2026
Article
Case study: Protecting Phase 2 obesity retention and study timelines
Mar 18, 2026
CTB Webinar
Extend your funding runway: How to maintain capital efficiency in an improving market
Mar 10, 2026
Blog
Bolster your investor narrative with RWE
Jan 26, 2026
Related Insights
CTB Blog
EMA’s new pre-submission interactions model pilot: A fundamental shift toward submission readiness and predictable reviews
Sep 30, 2026
CTB Blog
Engage early, design once: turning early-phase trials into a program strategy
Sep 10, 2026
CTB Blog
Five Practical Strategies for Accelerating Early Phase Studies
Aug 19, 2026
Article
Reading current FDA and NMPA trends: What oncology tells us about the changing regulatory landscape
Jul 21, 2026
CTB Blog
Modernizing data operations to enable today's Phase 1 trials
Jul 1, 2026
Blog
A Deep Dive into the Genetic Therapies Bootcamp at the ACMG 2026 Annual Meeting
Jun 23, 2026
Video
Bench-to-bedside: Transforming scientific breakthroughs into clinical success
Apr 3, 2026
CTB Blog
Even when capital flows freely, biotechs benefit from efficiency
Mar 24, 2026
CTB Blog
5 ways to secure biotech funding in 2026
Mar 19, 2026
Article
Case study: Protecting Phase 2 obesity retention and study timelines
Mar 18, 2026
CTB Webinar
Extend your funding runway: How to maintain capital efficiency in an improving market
Mar 10, 2026
Blog
Bolster your investor narrative with RWE
Jan 26, 2026

